# A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

> **NCT00938587** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 86 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** PF-04171327 10 mg
- **OTHER:** Prednisone Placebo
- **DRUG:** PF-04171327 25 mg
- **OTHER:** Prednisone Placebo
- **DRUG:** Prednisone 5 mg
- **OTHER:** Placebo for PF-04171327
- **OTHER:** Placebo
- **OTHER:** Placebo for PF-04171327

## Key facts

- **NCT ID:** NCT00938587
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-07
- **Primary completion:** 2010-07-29
- **Final completion:** 2010-07-29
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00938587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00938587, "A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00938587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*